Biotech Industry Discussion - The Biotech Forum has been actively discussing lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months [1] - The community provides real-time trading ideas and insights from seasoned biotech investors [1] Amphastar Pharmaceuticals (AMPH) - Amphastar Pharmaceuticals is being highlighted for the first time since May 2024 [2] - The stock has declined by just over 25% from its recent highs [2] Biotech Forum Services - The Biotech Forum offers a model portfolio featuring 12-20 high-upside biotech stocks [2] - The group provides live chat for trade discussions, weekly research, and option trades [2] - Market commentary and portfolio updates are provided every weekend [2]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36509 | --- | --- | |------------------------------------------------------------------------------------------------ ...

Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) Q3 2024 Earnings Conference Call November 6, 2024 5:00 PM ET Company Participants Bill Peters - CFO Dan Dischner - SVP of Corporate Communications Conference Call Participants Ekaterina Knyazkova - JPMorgan Pavan Patel - Bank of America David Amsellem - Piper Sandler Operator Greetings and welcome to the Amphastar Pharmaceuticals Inc. Third Quarter Earnings Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow ...

For the quarter ended September 2024, Amphastar Pharmaceuticals (AMPH) reported revenue of $191.21 million, up 5.9% over the same period last year. EPS came in at $0.96, compared to $1.15 in the year-ago quarter.The reported revenue represents a surprise of -2.51% over the Zacks Consensus Estimate of $196.15 million. With the consensus EPS estimate being $1.01, the EPS surprise was -4.95%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare ...

Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.96 per share, missing the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.15 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -4.95%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $0.78 per share when it actually produced earnings of $0.94, delivering a surprise of 20.51%.Over t ...

EXHIBIT 99.1 Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024 Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024 RANCHO CUCAMONGA, CA – November 6, 2024 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024. Third quarter Highlights ● Net revenues of $191.2 million for the third quarter ● GAAP net income of $40.4 million, or $0.78 p ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Considering these trends, value investing is clearly one of the most preferred ways to find strong stocks in any type of market. Value investors use tried-and-true metrics a ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Amphastar Pharmaceuticals (AMPH) . This company, which is in the Zacks Medical - Generic Drugs industry, shows potential for another earnings beat.When looking at the last two reports, this specialty pharmaceutical company has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 27.79% ...

ozgurcankaya My background isn't in medicine, so I tend to spend some extra time when a pharmaceutical company shows up on my screeners. It's not that I'm suspicious of the industry but that I feel the need to better understand the operation that the company is engaged in. Today, I'm going to be looking at Amphastar Pharmaceuticals (NASDAQ:AMPH), a company that engages in interesting types of administration of prescriptions and over-the-counter medication. We'll be looking at what the company offers, the pr ...

sefa ozel The S&P 500 fell over 8% in a three-week selloff amid fears of recession. The market bounced back last week despite big tech AI bubble fears triggered by weak jobs data and uncertainty over the impact and timing of Fed emergency rate cuts. The Tech (XLK) and Consumer Discretionary (XLY) sectors led the free fall, plunging by 15% and 12%, respectively, followed by the Industrial (XLI) and Energy (XLE) sectors, which both fell over 5%. Three defensive sectors - real estate, staples, and utilitie ...